The SAGE meeting of 8-10 October 2019 took place at in the EB conference room, WHO-HQ, Geneva. Available on this site you will find meeting information, background reading materials and presentations made at the meeting. The conclusions and recommendations of SAGE meeting are published in the WHO Weekly Epidemiological Record in English and French within two months of each SAGE meeting.
Meeting materials
Related
SAGE Yellow Book for October 2019
SAGE tracking record of recommendations and action points
Twenty-Fifth Meeting of the Technical Advisory Group (TAG) on Vaccine-preventable Diseases, 9-11 July 2019, Cartagena, Colombia
28th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region, 18-21 June 2019, Manila, Philippines
Tenth Meeting of the WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG), New Delhi, India, 9 to 12 July 2019
The 6th Annual meeting of the WHO Product Development for Vaccines Advisory Committee (PDVAC) WHO Headquarters, Geneva 26-28 June 2019
Immunization Practices Advisory Committee (IPAC) 13th meeting 11-13 June 2019. Final meeting report and recommendations
Report of the Global Advisory Committee on Vaccine Safety (GACVS), 5-6 June 2019. WER No. 28, 2019
Immunization and vaccines related implementation research advisory committee (IVIR-AC), recommendations. March 2019, WER No. 19, 2019
Global report including key updates and challenges from regions. - K. O'brien
No background documents provided for this session.
No background documents provided for this session.
Report from the Vaccine Innovation Prioritisation Strategy (VIPS) - M. Menozzi-Arnaud & B. Giersing
Feasibility Assessment of Measles and Rubella Eradication
Cost-Effectiveness of Measles Rubella Elimination
Session introduction - N. Turner
Rubella vaccine policy update - S. DesaiGlobal update on measles and rubella, including on outbreaks - K. Kretsinger
Modelling the epidemiologic impact and cost-effectiveness of different MR programme performance scenarios - M. Ferrari & M. Jit
SAGE Working Group on potential contribution of Human Papillomavirus (HPV) vaccines and immunization towards cervical cancer elimination: Background Document and Report to SAGE
Off-label HPV vaccine recommendations: a survey of NITAGs and EPI program managers
Final one dose HPV vaccine report v4
Final longer interval versus shorter interval of HPV vaccines
Final Two doses of HPV vaccine in 15-18 year old
MI4 Market Information for Access to vaccines - demand methodology
Session introduction and key questions - R. Aggarwal
Update on access to HPV vaccine - P. Bloem
Systematic review of evidence on different HPV immunization strategies - N. Henschke
Ongoing trials on single-dose HPV vaccine schedule - A. Kreimer
Global analysis of HPV vaccine supply and demand - T. Cernuschi
Impact of different HPV immunization strategies in the context of supply constraint - M. Brisson
Executive Summary: Global Vaccine Action Plan (GVAP) review and Immunization Agenda 2030 session
GVAP review and lessons learned
Immunization Agenda 2030: A Global Strategy to Leave No One Behind. Draft for SAGE
Report on GVAP review and lessons learned: Methodology, analysis and results of stakeholder consultations
The GVAP Monitoring, Evaluation and Accountability (M&E/A) Framework: Review and lessons learned
National Immunization Coverage Scorecards 1999-2018
Presentation of draft GVAP review and lessons learned report, including recommendations - N. Macdonald
Presentation of the draft post-2020 global immunization strategy (“Immunization Agenda 2030”) - K. O'brien
Ebola virus disease – Democratic Republic of the Congo Disease outbreak news: Update
Ebola virus disease: DRC- external situation report
Strategic Advisory Group of Experts (SAGE) on Immunization Interim Recommendations on Vaccination against Ebola Virus Disease (EVD) 7 May 2019
Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response.
Overview of candidate Ebola vaccines as of August 19, 2019
R&D Blueprint: Overview of the current research, development and use of vaccines against ebola (Made available online post meeting)
R&D Blueprint: Overview of the evidence and recommendations (Made available online post meeting)
Overview of SAGE recommendations and introduction to the session - F. Were
Update on outbreak epidemiology - B. Archer
Status of implementation of SAGE interim recommendations - A. Diallo
Preliminary observations regarding effect of rVSV ZEBOV vaccination in the Democratic Republic of the Congo (DRC) - A.M. Henao-Restrepo
Update on status of Ebola candidate vaccines and ongoing efforts towards global vaccine security - A. Costa
SAGE Working Group on Quality and Use of Immunization and Surveillance Data: Executive Summary
Immunization Data: Evidence for Action (IDEA) Precis.
India Case Study: Utilization of Immunization Data to Improve Evidence-based Decision-Making
Excerpt from the draft 2019 Western Pacific Region (WPR) 28th Technical Advisory Group (TAG) Meeting report summarizing presentations on the draft “Regional strategic framework for vaccine-preventable diseases and immunization in the Western Pacific, 2021-2030”
SAGE Data WG report with updated references
Annexes for the report of the SAGE working group on Quality and Use of Immunization and Surveillance Data
SAGE Immunization Data WG summary- H. Scobie
India: Utilization of Immunization Data to Improve Evidence-based Decision-Making - D. Ahmed
Western Pacific Region: data in the Regional Strategic Framework for Vaccine-preventable Diseases and Immunization 2021-2030 - D.A.C. Amarasinghe
SAGE Immunization Data WG proposed recommendations - J. Jawad
18th Meeting of the SAGE Polio Working Group. Conclusions and recommendations. Note for the Record.
Presentation of clinical data from nOPV2 trials and plan for EUL
Summary of PRELIMINARY results ahead of print: Immunogenicity of mOPV2 administered as 1-drop or 2-drops
GRADE table: Immunogenicity conferred by 1 vs 2 drops of monovalent oral poliovirus vaccine type 2 vaccine
Update from the Global Polio Eradication Initiative - R. Sutter
Presentation of clinical data from novel type 2 oral polio vaccine (nOPV2) trials and plan for Emergency Use Listing (EUL) - A. Bandyopadhyay
Report from SAGE Polio Working Group including presentation of results from “One-drop monovalent type 2 oral polio vaccine (mOPV2) study”; and call for acceleration of assessment of nOPV2 under EUL - I. Jani